Rapport Therapeutics, Inc. Common Stock (RAPP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has a cash flow conversion efficiency ratio of -0.129x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.52 Million) by net assets ($422.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RAPP market cap overview for the company's overall valuation and market capitalisation.
Rapport Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rapport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Rapport Therapeutics, Inc. Common Stock cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Guangzhou Daily Media Co Ltd
SHE:002181
|
0.028x |
|
Fujian Snowman Co Ltd
SHE:002639
|
-0.035x |
|
Dime Community Bancshares, Inc.
NASDAQ:DCOM
|
0.032x |
|
Shanghai Luoman Lighting Technologies Inc.
SHG:605289
|
0.015x |
|
Blackline Inc
NASDAQ:BL
|
0.142x |
|
FRIEDR.VORW.GRP. ADR/025
F:VH20
|
0.147x |
|
Marqeta Inc
NASDAQ:MQ
|
88.289x |
|
Fengzhushou Co. Ltd. A
SHE:301382
|
N/A |
Annual Cash Flow Conversion Efficiency for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025. View RAPP share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $484.65 Million | $-87.47 Million | -0.180x | +14.97% |
| 2024-12-31 | $305.43 Million | $-64.83 Million | -0.212x | -120.02% |
| 2023-12-31 | $-25.63 Million | $-27.18 Million | 1.060x | +737.94% |
| 2022-12-31 | $19.50 Million | $-3.24 Million | -0.166x | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more